8-K current report · filed Oct 15, 2026

Tonix Pharmaceuticals Holding Corp. (TNXP) 8-K Current Report: October 15, 2026

Item 2.02Item 8.01TNXP overview

Short answer

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on October 15, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Preliminary Q3 2026 TONMYA net revenue estimated at $14.0 million to $15.0 million.

Tonix Pharmaceuticals Holding Corp. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary Q3 2026 TONMYA net revenue estimated at $14.0 million to $15.0 million
  • Cash and cash equivalents approximately $162.8 million as of September 30, 2026
  • Revenue range provides an early read on TONMYA commercialization and near-term liquidity
  • Results remain unaudited and subject to quarter-end adjustments, potentially materially different from estimates

Item 8.01 · Other Events

  • Item 8.01 incorporates the Item 2.02 earnings disclosure by reference
  • Investor focus remains on the separate Item 2.02 exhibit for financial results or operating updates

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tonix Pharmaceuticals Holding Corp. 8-K filings

Get the next TNXP 8-K as it lands

Follow TNXP for push alerts, or ask the research agent what this filing means.